First Horizon Advisors, Inc. Exelixis, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.58 Billion
- Q3 2024
A detailed history of First Horizon Advisors, Inc. transactions in Exelixis, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 339 shares of EXEL stock, worth $11,505. This represents 0.0% of its overall portfolio holdings.
Number of Shares
339
Previous 339
-0.0%
Holding current value
$11,505
Previous $7,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding EXEL
# of Institutions
502Shares Held
243MCall Options Held
2.54MPut Options Held
2.29M-
Black Rock Inc. New York, NY33.5MShares$1.14 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.3MShares$995 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA25.4MShares$862 Million3.31% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.4MShares$521 Million0.63% of portfolio
-
State Street Corp Boston, MA11.4MShares$388 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $10.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...